aimovig tell headach split
aimovig pois market leader
host physician expert dinner us pharma team note discuss
outlook calcitonin gene-rel peptid cgrp treatment migrain expert
particip one largest headach practic us overal came
away posit event doctor view aimovig effect therapi
indic interest priorit aimovig first-lin prevent treatment
reimburs permit believ aimovig pois becom market leader
migrain treatment could potenti take market share year
signific pent-up demand aimovig
expert indic patient eagerli inquir aimovig patient
respond triptan patient botox insuffici respons
one physician alreadi prescrib aimovig migrain patient first two
month see signific pent-up demand aimovig sever reason
strong efficaci safeti clinic trial larg number migrain patient
unsatisfi current treatment payer may restrict
aimovig given reason price current payer requir one two prior line
therapi approv botox
posit initi feedback aimovig
initi feedback aimovig posit expert believ drug similar
efficaci safeti profil real world set compar phase trial result
accord expert two case patient rash
unclear whether drug relat concern given low rate
worth monitor addit free-drug trial user friendli
aimovig great start
ask expert view aimovig vs cgrp drug one
expect market share peak prefer aldr adler
biopharmaceut iv drug due complianc rais peak sale estim
aimovig rais ep reiter buy rate
aimovig encourag launch trajectori lift price object
unchang methodolog
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
biopharmaceut compani
develop manufactur market biolog
therapi oncolog inflamm
five key market product among top
sell pharmaceut product world
collect revenu
buy rate base belief
consensu revenu estim overestim
impact price pressur competit
top line addit new product
launch anticip biosimilar launch
help drive top-lin growth potenti
repatri signific portion
cash held oversea open door
potenti share buyback dividend payment
aimovig multipl advantag cgrp
first-mov advantag also auto-injector like
advantag teva fremanezumab viscou formul use pre-fil
syring aldr iv drug eptinezumab requir quarterli visit clinic may
less practic view lastli doctor meet believ unlik
agn oral cgrp atogep achiev similar efficaci mab
concern potenti liver toxic howev ultim success may also
depend insur coverag expect rel consist among
price object base multipl ep estim
non-gaap ep exclud stock option expens amort intang asset
restructur charg non-cash expens multipl support
strong cash flow gener dividend payout choic multipl
line major pharma peer
downsid risk po greater-than-forecast declin esa neupo
enbrel revenu greater-than-expect price pressur europ potenti drug
price system restructur us failur bring new pipelin product
upsid risk po less-than-forecast declin key product revenu
ying huang herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
